Preclinical Imaging Shared Facility

成像集团 临床前成像共享因子（PCISF） 摘要 临床前成像共享设施（PCISF）通过支持50多个项目， 五个项目的成员，进行癌症检测和治疗评估的临床前成像研究。的 该设施为新的癌症治疗方法提供详细的成像评估，从而加速其转化 进行人体试验具体目标如下：（1）提供最先进的分子成像技术， 在适当的动物模型中进行临床前研究，并支持IND过渡到人体成像研究;（2） 为CCC成员提供癌症模型分子成像的咨询和培训;（3）建立 图像分析方法;（4）维护仪器并保持其准确校准;以及（5） 开发新的成像技术和获取新的仪器。该设施将协调现有的支持 在UAB成像的机制，并显着扩大与临床相关的成像工作 可以转化为人类。成像组件包括结构和代谢成像（MRI/MRS， 高频超声和微型CT），γ射线成像（γ照相机，微型SPECT/CT， microPET/CT、PET/MR）和光学成像（生物发光和荧光）。PCISF承诺 一种多模态成像方法，通过以下方式提供对动物模型中癌症的分子理解： 整合肿瘤质量测量（生物发光、超声、CT和MR）、肿瘤特异性靶向 （SPECT、超声、荧光、microPET）、血管参数（超声、MR）和特定治疗 响应（超声、生物发光、SPECT、MR、micoPET）。每种成像方式都有优点， 它们的协调应用是协同的。该设施满足了评估新疗法的关键需求， 在动物模型中的癌症，从而使新疗法的翻译到人体试验。该设施将 提高其他UAB-CCC共享设施（高分辨率成像，组织采购， 质谱/蛋白质组学，转基因动物和人类成像），通过提供实时成像， 活动物中的分子途径，使精确的组织取样和微量分析，并促进 翻译成人类研究。

IMAGING GROUP PRECLINICAL IMAGING SHARED FACILITY (PCISF) ABSTRACT The Preclinical Imaging Shared Facility (PCISF) fulfills a critical UAB-CCC priority by supporting over 50 members in five programs with preclinical imaging studies for detection of cancer and therapy evaluation. The facility provides detailed imaging evaluation of new cancer treatments, and thereby accelerates their translation to human trials. The specific aims are the following: (1) to provide state-of-the-art molecular imaging for preclinical studies in appropriate animal models, and support IND's for transition to human imaging studies; (2) to provide consultation and training to CCC members for molecular imaging in cancer models; (3) to establish methods for image analyses; (4) to maintain the instruments and keep them accurately calibrated; and (5) to develop novel imaging technologies and acquire new instruments. The facility will coordinate existing support mechanisms for imaging at UAB, and significantly expand the imaging effort with clinically relevant imaging that can be translated to humans. Imaging components include structural and metabolic imaging (MRI/MRS, high frequency ultrasonography and microCT), gamma-ray imaging (gamma camera, microSPECT/CT, microPET/CT, PET/MR), and optical imaging (bioluminescence and fluorescence). The PCISF has undertaken a multimodality imaging approach to provide a molecular understanding of cancer in animal models by integrating measurements of tumor mass (bioluminescence, ultrasound, CT, and MR), tumor specific targeting (SPECT, ultrasound, fluorescence, microPET), vascular parameters (ultrasound, MR), and specific therapy responses (ultrasound, bioluminescence, SPECT, MR, micoPET). Each imaging modality has advantages and their coordinated application is synergistic. The facility meets a critical need in evaluation of new therapies for cancer in animal models, thereby enabling translation of the new therapies to human trials. The facility will enhance the potential of other UAB-CCC shared facilities (High Resolution Imaging, Tissue Procurement, Mass Spectrometry/Proteonomics, Transgenic Animal, and Human Imaging) by providing real-time imaging of molecular pathways in the living animal, enabling precise tissue sampling and microanalyses, and facilitating translation to human studies.